Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Humira has enjoyed high-priced U.S. exclusivity for 20 years. Its challengers could save the health care system $9 billion and herald savings from the whole class of drugs called biosimilars.

Related Keywords

Kentucky ,United States ,United Kingdom ,Tennessee ,Denmark ,Poland ,California ,Brooklyn ,New York ,Americans ,American ,Mark Cuban ,Paul Holmes ,Madelaine Feldman ,Kaiser Permanente ,Siddharth Singh ,Mary Beth Lang ,Greg Baker ,Alex Jung ,Keith Athow ,Coherus Biosciences ,Juliana Reed ,Cora Opsahl ,Richard Gonzalez ,Michael Thompson ,Antonio Ciaccia ,Kevin Ali ,Rachel Shubert ,Bj Health Fund ,American Gastroenterological Association ,Midwest Business Group On Health ,Biosimilars Forum ,Health News ,Service Employees International Union ,American College Of Rheumatology ,Kroger ,National Alliance Of Healthcare Purchaser Coalitions ,Arthur Allen ,Williams Barber Morel ,Express Scripts ,Federal Trade Commission ,Blue Shield ,Cost Plus Drugs ,Sue Lee ,National Alliance ,Healthcare Purchaser ,Midwest Business Group ,Marcus Snow ,American College ,New Orleans ,Gastroenterological Association ,Inflation Reduction Act ,Rich Lieblich ,